Brigham-Led Clinical Trial Finds Finerenone Reduces Worsening Heart Failure and Cardiovascular Death
September 10, 2024
September 10, 2024
BOSTON, Massachusetts, Sept. 10 -- Mass General Brigham issued the following news release:
* * *
In a randomized, placebo-controlled trial, the drug improved outcomes in patients with heart failure and mildly reduced or preserved ejection fraction.
* * *
Finerenone reduced the composite of total first and recurrent heart failure (HF) events (hospitalizations for HF or urgent HF visits) and cardiovascular death in patients with HF and mildly red . . .
* * *
In a randomized, placebo-controlled trial, the drug improved outcomes in patients with heart failure and mildly reduced or preserved ejection fraction.
* * *
Finerenone reduced the composite of total first and recurrent heart failure (HF) events (hospitalizations for HF or urgent HF visits) and cardiovascular death in patients with HF and mildly red . . .